Haematology Flashcards
(137 cards)
haemostats
is the cessation of bleeding, has three stages:
Vascular
Platelet
Coagulation
These occur in conjunction with each other as a result of multiple cascades
Haemostasis requires interaction of platelets, coagulation and fibrinolytic factors, endothelium,
Proinflammatory and anti-inflammatory mediators and leukocytes
Clot formation is initiated by vascular injury, in which a platelet plug forms and is reinforced
With fibrin produced via the extrinsic pathway
coagulation cascade
At the site of vessel injury platelets will arrive at the site to begin the clotting cascade
Involves extrinsic and intrinsic pathway
Extrinsic pathway:
Begins with now exposed molecules of the tissue wall such as tissue factor (contact system initiated)
Forms a complex with factor VIIa leading to activation of factor Xa
Point of Xa activation is point at which the extrinsic and intrinsic pathway meet
Intrinsic pathway:
Various coagulation factors such as IXa, XIa, XIIa which activate in cascade
An additional cofactor (VIIIa and IXa) combine with Xa to activate factor Xa (where pathways merge)
Combined pathway:
Xa is pivotal factor of clotting cascade
Xa combines with Va and Prothrombin further down cascade, catalysing prothrombin and inducing the ‘thrombin burst’
One Xa factor can catalyse 10,000 prothrombin to thrombin reactions
These large amounts of thrombin induce further platelet action and enhanced formation of fibrin
Fibrin forms strands which form the mesh that stabilises the clot during an arterial clot and holds the RBC together in a venous clot
Xa is a viable target for therapeutics involving pathological coagulation cascades
RBCs
7um diameter
No nucleus
Life span 100-120 days
Consists of 640 million molecules of hemoglobin (Hgb)
RBC count = total number of Hgb
Transports oxygen and CO2
Each Hgb transports four O2 molecules (oxyhaemoglobin) which carries to individual cells
Also binds to CO2 (carboxyhemoglobin), presence of CHgb helps release O2 from Hgb molecules
Haematological investigations for surgeries
Haematology is the study of blood components form and function and the coagulation system
Pre-operative care:
Assessment, diagnosis, management of safety issues
Preparation of patient centred care and decision making: pre op blood ordering, anaemia management, diabetes management, anticoagulation therapy management
Perioperative haem Ix:
Diagnostic assessment: diagnosis of blood diseases and abnormalities (e.g. patients general health)
Check for existing anaemias: bone marrow cancers, chemotherapy, vit B12/iron deficiencies, malabsorption disorders, liver disease, renal disease, anaemias, blood loss etc.
Prognostic assessment: identifies possibility of developing abnormal functioning blood, effective oxygenation and coagulation (e.g. how patients respond to their operations)
FBC
RBC: haemoglobin and haematocrit (in total)
WBC: differential count
Platelet count
Indications: Measures total Hgb or Hb in blood Indirect RBC measure Assessment of ongoing bleeding Evaluation of anaemic patients Normal range:
Male - 14-18 g/dl or 8.7-11.2 mmol/l
Female - 12-16g/dl or 7.4-9.9 mmol/l
Pregnancy - 11g/dl
Newborn - 14-24 g/dl
0-2 weeks - 12-20 g/dl
2-6 months - 10-17 g/dl
6 months - 6 years - 9.5-14 g/dl
6-18 years - 10-15.5g/dl
Elderly - Slightly decreased
indications of increased and decreased Hb
Indication of increased Hgb: Erythrocytosis Congenital heart disease Severe COPD Polycythaemia vera Severe dehydration
Indication of decreased Hgb: Anaemia Haemoglobinopathy Cirrhosis Haemolytic anaemia Haemorrhage Dietary deficiency Bone marrow failure Renal disease Normal pregnancy Rheumatoid/collagen vascular disease Haemolytic cancer Splenomegaly
RBC indices
Mean cell/corpuscular volume (MCV): average RBC size (80-100fL in adults)
Mean cell haemoglobin (MCH): average weight of RBCs (26-32 picogram)
Mean cell haemoglobin concentration (MCHC): average concentration of Hgb in RBCs (32-36g/dL)
haematocrit
volume % of RBC in whole blood.
Indication of Ix: Indirect measure of RBC no. and volume Rapid indirect measure of RBC count Serial assessment in ongoing bleeding Integral part of anaemic patient evaluation
Normal range:
Male - 42-52% or 0.42-0.52
Female - 0.37-0.47
Pregnancy - >0.33
Newborn - 0.44-0.64
2-8 weeks - 0.39-0.59
2-6 months - 0.35-0.50
6 months - 1 year - 0.29-0.43
1-6 years - 30-40%
6-18 years - 32-44%
Elderly - Slightly decreased
HCT/interfering factors:
Abnormality in RBC size
Haemodilution and dehydration
Unreliable levels immediately after haemorrhage
Extremely elevated WBC gives a decreased HCT (false anaemia)
Pregnancy shows decreased HCT
Chloramphenicol and penicillin both decrease levels
Living at high altitude increases HCT levels
WBC tests
evaluate infection, neoplasm, allergy and immunosuppression
- Total WCC
- Differential WBC count (different proportions of various WBC types)
Normal ranges:
Adults and children 2+ - 500-10,000/mm3 or 5-10 x10(9)/L
Children <2 - 6200-17,000/mm3
Newborn - 9000-30,000/mm3
neutrophils:
Phagocytosis of pathogens
55-70% normal
Lymphocytes
Natural killer cells, T and B lymphocytes
20-40% normally
B lymphocytes
Make Ig antibodies
T lymphocytes
Cooperate antibody production and attack infected cells
Monocytes
Phagocytosis
2-8% normally
Eosinophils
Phagocytose antigen-antibody complexes
1-4% normally
Basophils
Immune response to parasites and allergic reactions (hay fever)
0.5-1% normally
leukocytosis and leukopenia indications
Increased WBC indications (leukocytosis): Infection Neoplasia Malignancy Trauma, stress, haemorrhage, tissue necrosis Inflammation Dehydration Thyroid storm Steroid use
Decreased WBC indications (leukopenia): Drug toxicity Bone marrow failure Overwhelming infection Dietary deficiency (B12/iron) Bone marrow infiltration Autoimmune disease Hypersplenism (spleen extracts WBC aggressively)
coagulation screen tests
Platelet count (thrombocyte count PLT)
Clotting tests: prothrombin time (PT), fibrinogen, activated partial thromboplastin time (APTT), thrombin time and D’DIMER
APTT, PLT, PT and fibrinogen are standard coagulation tests prior to CV operations
Clotting screen normal range: Hb (g/dl) - Male: 13.5-18 or Female: 11.5-16 PT (s) - 12-13 aPTT (s) - 30-40 aPTT ratio - 1 (normal patient aPTT:present patient aPTT) INR - 1 Platelets (L) - 150-400 x10 (9) Fibrinogen (g/l) - 1.5-3
platelets
Forms in bone marrow
Small, round, non nucleated
Main role is maintenance of vascular integrity
Primary phase of hemostasis involves platelet aggregation
Platelet aggregation initiates the coagulation factor cascade
Normal values:
Premature infant - 100,000-300,000/mm3
Newborn - 150,000-300,000mm/3
Infant - 200,000-475,000/mm3
Child, Adult and elderly - 150,000-400,000/mm3
Greater than (thrombocytosis)
Less than (thrombocytopenia) Symptoms: easy bruising and frequent bleeding from gums, nost, GIT Caused by medications, congenital, leukaemia or lymphomas, chemotherapy, kidney infection/disease, excessive alcohol intake
fibrinogen
Normal range 60-100mg/dl or 1.5-4g/l
Derived from PT reaction as it occurs
Primarily a screen: any low fibrinogen detected is substituted for clauss fibrinogen test which measure fibrinogen directly
In disseminated intravascular coagulation the derived fibrinogen may be misleading
D’DIMER
Most notable subtype of fibrin degradation products
Levels of FDPs rise after any thrombotic event
Fibrin and fibrinogen degradation product (FDP) testing is commonly used to diagnose disseminated intravascular coagulation (DIC), PE, DVT, pregnancy, malignancy
During formation of a stable clot, amino acids are excised by various enzyme cascade reactions
The D’DIMER peptide is excised from the D portion of fibrin as the clot hardens
Therefore it is a useful predictor of recent clot formation
normal value:
for DIC in adult - 0.08-0.18 ugFEU/mL
for DVT/PE in adult - cut off for exclusion of VTE: <0.35ugFEU/mL
prothrombin time and INR
PT: time taken in seconds for blood to clot. Measures vitamin K dependent clotting pathways (extrinsic) therefore particularly measures warfarin activity (vit K antagonist)
PT and INR are calculations that monitor effectiveness of warfarin anticoagulation therapy
INR shows required dosage of warfarin to maintain balance between preventing clots and causing excessive bleeds for patients (aim for 2.5; between 2-3 in patients on warfarin)
Normal PT: 11-12.5 seconds
Full anticoagulant therapy: >1.5-2 x control value; 20-30%
Normal INR: 0.8-1.1
partial thromboplastin time PTT and thrombin time TT
Normal PTT: 60-70 seconds. Measures intrinsic clotting pathway, time taken for blood to clot. Useful in monitoring heparin therapy
Normal aPTT: 30-40 seconds. Provides ratio of APTT:normal clotting time and is primary calculator used to monitor heparin therapy
Thrombin time (TT):
Normal TT: 12-15 seconds. Measures time taken for fibrinogen to form fibrin (later clotting common pathway stage)
Primarily requested in liver disease units
operative haemorrhage and blood products
Primary bleeding: occurs within the intraoperative period. Resolved within operation. Major haemorrhages are recorded and patient monitored closely post operatively
Reactive bleeding: occurs within 24 hours of operation. Mainly from ligature slips or missed vessels (due to hypotension and vasoconstriction during operation). Once BP normalises post op this bleeding will occur
Secondary bleeding: occurs within 7-10 days post op. Due to erosion of a vessel from a spreading infection. Often seen when heavily contaminated wound is closed primarily
Blood products: Whole blood Packed RBCs Fresh frozen plasma (FFP) Platelet concentrates Cryoprecipitate
Thromboelastography TEG
Test of whole blood coagulation
Been shown to decreased usage of blood products and mortality during procedures (good for trauma)
May be used to screen patients for coagulopathy in blunt/penetrating trauma with hemorrhagic shock, those receiving massive transfusion protocol (1:1:1) to evaluate for discontinuation or guided product therapy or clinical suspicion for haemorrhage or coagulopathy
blood transfusion complications
Immunological complications Wrong blood episodes/errors Infections Immunomodulation Litigation
Early complications are rare but tend to be much more severe:
Acute haemolytic transfusion reaction: incompatible RBCs transfused. May lead to DIC. ABO incompatible transfusion has 10% mortality while non-ABO is less severe usually but can still cause intravascular hemolysis
Infective shock: bacterial contamination is rare but can be fatal. Acute onset hypotension, rigors and collapse rapidly following transfusion. Platelets more likely to be contaminated than RBCs
Transfusion related acute lung injury: acute respiratory distress due to donor plasma containing antibodies against patients’ leukocytes. <6 hours onset nonproductive cough, SoB, hypoxia and frothy sputum. May have fever and rigors. CXR shows multiple perihilar nodules with lower lung infiltration. Usually from multiparous women who have become alloimmunized
Fluid overload: too much fluid leading to pulmonary oedema, acute respiratory failure. Those at particular risk have chronic anaemia (normovolaemic/hypervolemic) or symptoms of cardiac failure prior to transfusion
Non-haemolytic febrile reaction to transfusion of platelets and RBCs: fevers and rigors can develop due to patients’ antibodies to transfused white cells. Multiparous women who have received multiple previous transfusions are most at risk. Not life threatening reaction, treat by slowing transfusion and paracetamol
Anaphylaxis: antibodies react to proteins in transfused blood components, release IgE or IgG antibodies. Urticaria and itching common within minutes of transfusion starting
haemoglobin
Protein in RBCs that carries O2 from the lungs to body tissues and returns CO2 from tissues to lungs
Made of four protein molecules (globulin chains) that are each connected and a heme (Fe containing porphyrin) totalling 8 components
Also plays role in maintaining the shape of the RBCs and helping maintain acid-base balance within circulation
blood
8% body weight
Blood is a connective tissue: made of living cells suspended in a non-living matrix (plasma)
Main function: transportation of oxygen, nutrients, hormones and signalling molecules
Whole blood contains: Red cells Platelets Plasma Cryoprecipitate (protein for blood clotting)
Centrifuge separates whole blood into three distinct layers:
Erythrocyte layer on bottom (red)
White cell and platelets layer in middle
Yellow plasma (55% blood volume) full of proteins, waste products, electrolytes and plasma proteins (albumin, alpha/beta globulins) mostly made in the liver
blood types
O, A, B, AB refers to type of antigen present (O = none present). Each type can also be Rh +ve or -ve making 8 types of blood
Each has a different glycoprotein in plasma membrane (antigen) that immune system can recognise
In different blood types, enter circulation will trigger an immune response due to unrecognised antigen present in the system.
Often targets foreign body with agglutination (sticking the cells together) which can cause clots
AB: universal recipients due to having both antigens so will recognise ALL blood types (O, A and B)
O: universal donor due to lack of antigens meaning it can be given to anyone of any blood type and not be detected by the immune system. However they are ONLY able to receive O type blood as immune system will detect and respond to both A and B antigens
Rhesus antigens: either have (+ve) or don’t (-ve)
Rhesus positive: can accept either +/-ve blood as they will recognise (do NOT have antibodies against) rhesus protein
Rhesus negative: stick to -ve donor blood as +ve will trigger immune response. Negative types can actually tolerate Rh+ve ONCE but after this they will develop antigens and lead to never accepting +ve blood again. This can be a problem in -ve mothers giving birth to +ve children if there is blood exchange. Is okay for one pregnancy but for any subsequent births she will need rhogam serum injection containing anti-rh antigens to block the mother’s immune response to her baby
erythropoietin cell cycle
Develop from committed stem cells to mature RBCs in about 7 days
Megakaryocyte erythroid progenitor (MEP), proerythroblast, early erythroblast, intermediate erythroblast, late erythroblast, nuclear erythroblast, nuclear extrusion, reticulocyte then RBC; each stage differentiates more by losing nuclei and proteins etc.
When matured in healthy individuals circulate for around 100-120 days (and 80-90 days in full term infant)
The regulation of formation is mostly from erythropoietin (EPO) from the kidneys (some in liver too) which is produced when hypoxia or low O2 levels are detected in the kidneys using hypoxia inducible factor (oxygen used to degrade/inactivate HIF so when hypoxic HIF signalling increases)
Old erythrocytes get more rigid and more likely to get stuck in capillaries. There are many channels to collect these older RBCs especially around the spleen (RBC graveyard) trapping old RBCs where macrophages engulf and digest components, separating them all into individual components for recycling or waste removal (amino acids, Fe stored in liver or put into new erythrocytes and haem turned into bilirubin for bile)
destruction process is called eryptosis
sickle cell anaemia
Autosomal recessive
Most common in african descent; must screen all african origin people for SCD pre-op
1/700 incidence
HbSS - homozygotes (SS) symptomatic sickle cell anaemia
HbAS - heterozygous - sickle cell trait (no symptoms but falciparum malaria resistant) may still experience symptomatic sickling hypoxia
SCD is most common in patients of africam indian, middle east and carribean descent as single copy of gene increases malarial resistance and is a selective advantage.
Pathology:
Foetal Hb (HbF) is usually replaced by HbA at around 6 weeks of age. Patients with SCD have an abnormal amount of variant Hb (HbS) which causes abnormal sickle shaped erythrocytes
Results from three interconnected sequelae of SCD
Vaso-occlusive crisis results in bone infarcts and subperiosteal haemorrhages
Chronic anaemia resulting in expansion of medullary spaces
Infection
These predispose individuals to complications such as growth disturbance and pathological fractures
Pathogenesis: Hypoxia Deoxygenated HbS Polymerises Deformity of RBCs, sickle cells cannot travel normally or carry oxygen Haemolysis + blocked small vessels